🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,557 results for “placebo” Clear

  1. Cemiplimab and Fianlimab - 1, Fianlimab, Cemiplimab & Fianlimab - 2, LIBTAYO 350 mg concentrate for solution for infusion., Placebo for Fianlimab

    Lacuna Pharma Pty Ltd

    Melanoma

    phase 2 small molecule active

    1 trial

  2. Cemiplimab and Fianlimab - 1, Placebo, LIBTAYO 350 mg concentrate for solution for infusion., PEMETREXED, CARBOPLATIN, CISPLATIN, Cemiplimab & Fianlimab - 2, PACLITAXEL

    Lacuna Pharma Pty Ltd

    Resectable Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  3. Cenegermin, The placebo for investigational lyophilized cenegermin Drug Product is the same as the Drug Product with the exception that it does not contain cenegermin.

    Dompe' Farmaceutici S.p.A.

    Spastic Cerebral Palsy

    phase 2 small molecule active

    1 trial

  4. Colesevelam hydrochloride-MMX® modified-release placebo tablets, Colesevelam hydrochloride-MMX® 900 mg modified-release tablets

    Cosmo Technologies Ltd

    bile acid diarrhoea (BAD)

    phase 2 small molecule active

    1 trial

  5. Crofelemer Placebo Powder for Oral Solution

    Lacuna Pharma Pty Ltd

    Microvillous Inclusion Disease (MVID)

    phase 2 small molecule active

    1 trial

  6. Crovalimab, Crovalimab, Crovalimab Placebo F01-01, Crovalimab

    Hoffmann-La Roche

    Paroxysmal nocturnal hemoglobinuria (PNH)

    phase 2 small molecule active

    1 trial

  7. DASATINIB, Placebo

    The George Institute

    Asymptomatic patients with recent HIV-1 infection

    phase 2 small molecule active

    1 trial

  8. DFV890, DFV890, Placebo to MAS825 100 mg/1 mL Solution for Injection, Placebo to DFV890 10 mg and 25 mg film-coated tablet, MAS825

    Novartis Pharmaceuticals

    Atherosclerotic cardiovascular disease

    phase 2 small molecule active

    1 trial

  9. DNTH103, Matching placebo to DNTH103

    Dianthus Therapeutics, Inc. /DE/

    Multifocal Motor Neuropathy

    phase 2 small molecule active

    1 trial

  10. DONEPEZIL ARROW 5 mg, comprimé pelliculé, The placebo has the same container composition as the investigational medicinal product (exception of the active substance) and is manufactured by the same manufacturer (pui of the brest university hospital) according to the same procedures as the investigational medicinal product. the active substance is lactose monohydrate, ARICEPT 5 mg, comprimé pelliculé, DONEPEZIL BIOGARAN 5 mg, comprimé pelliculé

    Pari Pharma GmbH

    Anorexia nervosa

    phase 2 small molecule active

    1 trial

  11. DYNE-101, The placebo is commercially available 0.9% (w/v) saline solution intended for IV

    Dyne Therapeutics

    Myotonic Dystrophy Type 1

    phase 2 small molecule active

    1 trial

  12. Daridorexant matching placebo, QUVIVIQ 50 mg film-coated tablets, QUVIVIQ 25 mg film-coated tablets

    Lacuna Pharma Pty Ltd

    Insomnia Disorder

    phase 2 small molecule active

    1 trial

  13. Decitabine/Tetrahydrouridine A 5/250 mg, Siklos 1 000 mg film-coated tablet., Placebo (NDec)

    NovoThirteen

    Sickle cell disease

    phase 2 small molecule active

    1 trial

  14. Description and Composition of the Placebo • Placebo oil solution matching the Cannabis Extract Avextra 10/10 Solution. • Pharmaceutical form: solution (oil) • Route of administration: oral • Storage: Store tightly closed below 25°C and protected from light like the verum form. • Country of origin: Italy., Cannabis Extract Avextra 10/10 Solution

    Fondazione Telethon ETS

    Patients with advanced oncologic disease receiving active treatment with WHO level II or III opioids and adjuvants therapies

    phase 2 small molecule active

    1 trial

  15. EB01 Cream Placebo

    Edesa Biotech

    Allergic Contact Dermatitis

    phase 2 small molecule completed

    1 trial

  16. EDP-938, EDP-938 Placebo tablets

    ENANTA PHARMACEUTICALS INC

    Respiratory syncytial virus (RSV)

    phase 2 small molecule active

    1 trial

  17. ENFORTUMAB VEDOTIN , mRNA-4157, Placebo to V940, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Muscle-invasive Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  18. ENTECAVIR , Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe, TENOFOVIR DISOPROXIL , TENOFOVIR ALAFENAMIDE , -, VAY736

    Novartis Pharmaceuticals

    Diffuse cutaneous systemic sclerosis (dcSSc)

    phase 2 small molecule active

    1 trial

  19. EPINEPHRINE NASAL SPRAY, Placebo Nasal Spray, EPINEPHRINE NASAL SPRAY

    Ars Pharmaceuticals Irl Limited

    Chronic Spontaneous Urticaria (CSU)

    phase 2 small molecule active

    1 trial

  20. ETIDRONATE DISODIUM ORAL CAPSULES 400 MG PLACEBO, ETIDRONATE DISODIUM ORAL CAPSULES 400 MG

    Disc Medicine

    Fahr's disease, Fahr's syndrome

    phase 2 small molecule active

    1 trial

  21. Eltrekibart, 0.9% sodium chloride, Mirikizumab, Mirikizumab, Placebo for LY3074828 SC Injection, 1mL Prefilled Syringe

    Eli Lilly Co.

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  22. Enpatoran Placebo, Enpatoran

    Merck Sharp and Dohme

    Systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE)

    phase 2 small molecule active

    1 trial

  23. Enpatoran placebo, Enpatoran, Enpatoran

    Merck Sharp and Dohme

    Systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE)

    phase 2 small molecule active

    1 trial

  24. FLORBETAPIR, Placebo to match LY, Flortaucipir, Donanemab

    Eli Lilly Co.

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources